Enzo Biochem, Inc(NYSE:ENZ)

Latest On Enzo Biochem, Inc (ENZ):

Updated on: March 19, 2021

Date/Time	Type	Description	Signal
2023-05-31 04:40 EST	News	Enzo Biochem says ransomware attack exposed patient info, Social Security numbers	N/A
2023-05-26 10:32 EST	News	Enzo Biochem files for $150M mixed shelf offering	N/A
2023-04-14 11:04 EST	News	Enzo Biochem slips after ransomware attack	N/A
2023-03-21 19:28 EST	News	Enzo Biochem GAAP EPS of -$0.23, revenue of $16.34M	N/A
2023-03-17 23:37 EST	News	Crypto stocks dominate premarket gainers	N/A

About Enzo Biochem, Inc (ENZ):

Enzo Biochem, Inc., an integrated diagnostics, clinical lab, and life sciences company, researches, develops, manufactures, and markets diagnostic and research products based on genetic engineering, biotechnology, and molecular biology. It operates through three segments: Products, Clinical Services, and Therapeutics. The Products segment develops, manufactures, and markets products and tools to clinical research, drug development, and bioscience research customers. It offers proteins, antibodies, peptides, small molecules, labeling probes, dyes, and kits, which provide life science researchers tools for target identification/validation, content analysis, gene expression analysis, nucleic acid detection, protein biochemistry and detection, and cellular analysis. This segment provides its p read more...roducts to scientific experts in the fields of cancer, cardiovascular disease, neurological disorders, diabetes and obesity, endocrine disorders, infectious and autoimmune disease, hepatotoxicity, and renal injury. The Clinical Services segment provides routine and esoteric clinical laboratory tests or procedures used in general patient care by physicians to establish or support a diagnosis, monitor treatment or medication, or search for an otherwise undiagnosed condition. It operates a full-service clinical laboratory in Farmingdale, New York; a network of 34 patient service centers in New York and New Jersey; and a free-standing ?STAT' or rapid response laboratories in New York City and Connecticut, as well as a full-service phlebotomy center and an in-house logistics department. The Therapeutics segment develops novel approaches in the areas of gastrointestinal, infectious, ophthalmic, and metabolic diseases. The company markets its products and services through its direct sales force and a network of distributors in the United States and internationally. Enzo Biochem, Inc. was founded in 1976 and is headquartered in New York, New York.

See Advanced Chart

General

Name Enzo Biochem, Inc
Symbol ENZ
Type Common Stock
Exchange NYSE
Currency USD
Country USA
SectorHealthcare
IndustryDiagnostics & Research
Full Time Employees 408
Last Split Factor105:100
Last Split Date2004-10-21
Fiscal Year EndJuly
IPO Date1980-06-12
Gic SectorHealth Care
Gic GroupHealth Care Equipment & Services
Gic IndustryHealth Care Providers & Services
Gic SubIndustryLife Sciences Tools & Services
Web URLhttp://www.enzo.com

Valuation

Trailing PE 100.67
Price/Sales (Trailing 12 Mt.) 1.99
Price/Book (Most Recent Quarter) 3.13
Enterprise Value Revenue 1.86

Financials

Most Recent Quarter 2021-01-31
Profit Margin -11%
Operating Margin -12%
Return on Assets -7%
Return on Equity -16%
Revenue 96.55 million
Earnings Per Share $0.03
Revenue Per Share $2.02
Gross Profit 23.77 million
Quarterly Earnings Growth 62.3%

Highlights

Market Capitalization 177 million
EBITDA -24087000
PE Ratio 1.31
Analyst Target Price $5.5
Book Value Per Share $1.28

Share Statistics

Shares Outstanding 48.23 million
Shares Float 35.19 million
% Held by Insiders 717%
% Held by Institutions 62.19%
Shares Short 1.89 million
Shares Short Prior Month 1.94 million
Short Ratio 5.85
Short % of Float 5%
Short % of Shares Outstanding 4%

Technicals

Beta 0.92
52 Week High $4
52 Week Low $1.8
50 Day Moving Average 3.11
200 Day Moving Average 2.5

Dividends

Dividend Date N/A
ExDividend Date N/A
Dividend Yield 0%

Enzo Biochem, Inc (ENZ) Dividend Calendar:

Show entries

Search:

Ex-Dividend Date	Payment Date	Record Date	Declared Date	Amount
No data available in table

Showing 0 to 0 of 0 entries

Enzo Biochem, Inc (ENZ) Earnings History:

Companies typically report earnings on both a quarterly and annual basis. Earnings reported that deviate from analysts' expectations can have a large impact on a stock's price.

Show entries

Quarter Date	Report Date	Actual Revenue	Reported EPS	EPS Estimate	Deviation from Estimate
2021-01-31	2021-03-16	$N/A	$0.05
2020-10-31	2020-12-09	$N/A	$0.01
2020-07-31	2020-10-31	$19.53 million	$0.01
2020-04-30	2020-07-31	$16.9 million	-$0.07
2020-01-31	2020-04-30	$19.38 million	-$0.21
2019-10-31	2020-01-31	$20.21 million	-$0.16
2019-07-31	2019-10-31	$20.92 million	-$0.16
2019-04-30	2019-07-31	$19.66 million	-$0.12	-$0.15	20.4%
2019-01-31	2019-03-11	$19.33 million	-$0.18	-$0.13	-38.46%
2018-10-31	2018-12-10	$21.26 million	-$0.13	-$0.11	-18.18%

Enzo Biochem, Inc (ENZ) Company Financial Statements:

Financial statements are reports prepared by a company's management to present their financial performance and position at a point in time. A general-purpose set of financial statements usually includes a balance sheet, income statements, and statement of cash flows.

Income Statement:

Date	Jan 31 2021	Oct 31 2020	Jul 31 2020	Apr 30 2020	Jan 31 2020
Research Development	N/A	N/A	N/A	1.16 million	N/A
Income Before Tax	N/A	N/A	-3.33 million	-9.86 million	-7.69 million
Selling General Administrative	N/A	N/A	10.07 million	11.06 million	N/A
Gross Profit	N/A	N/A	7.85 million	4.43 million	5.81 million
Ebit	N/A	N/A	N/A	-7.08 million	-7.69 million
Operating Income	N/A	N/A	-4.43 million	-7.8 million	-7.69 million
Income Tax Expense	N/A	N/A	N/A	N/A	N/A
Total Revenue	N/A	N/A	19.53 million	16.9 million	19.38 million
Cost of Revenue	N/A	N/A	11.68 million	12.48 million	13.58 million
Total Other Income Expense Net	N/A	N/A	N/A	-2.15 million	N/A
Net Income From Continuing Operations	N/A	N/A	N/A	-9.86 million	-7.69 million
Net Income Applicable to Common Shares	2.3 million	299000	-3.33 million	-9.86 million	-7.69 million

Cash Flow:

Date	Oct 31 2020	Jul 31 2020	Apr 30 2020	Jan 31 2020	Oct 31 2019
Investments	N/A	N/A	-285000	N/A	N/A
Change to Liabilities	-658000	N/A	334000	N/A	1.33 million
Total Cash Flow from Investing Activities	-617000	-2.17 million	-285000	N/A	-274000
Net Borrowings	-113000	N/A	7.32 million	N/A	-105000
Total Cash Flow from Financial Activities	N/A	7 million	7.32 million	N/A	-171000
Change to Operating Activities	1.17 million	N/A	2.35 million	N/A	2.12 million
Change in Cash	N/A	-12.28 million	2.91 million	N/A	-2.5 million
Total Cash from Operating Activities	-1.21 million	-17.18 million	-4.13 million	N/A	-2.07 million
Depreciation	N/A	2.26 million	717000	N/A	725000
Other Cash Flow from Investing Activities	N/A	N/A	N/A	N/A	N/A
Change to Inventory	N/A	N/A	-515000	N/A	310000
Change to Account Receivables	N/A	N/A	2.09 million	N/A	890000
Other Cash Flow from Financing Activities	N/A	N/A	N/A	N/A	-66000
Change to Net Income	530000	N/A	752000	N/A	209000
Capital Expenditures	N/A	2.17 million	285000	N/A	274000

Balance Sheet:

Date	Jan 31 2021	Oct 31 2020	Jul 31 2020	Apr 30 2020	Jan 31 2020
Total Liabailities	N/A	N/A	54.16 million	54.02 million	N/A
Total Stockholder Equity	N/A	N/A	58.38 million	62.33 million	N/A
Other Current Liabilities	N/A	N/A	N/A	7.15 million	N/A
Total Assets	N/A	N/A	112.54 million	116.35 million	N/A
Common Stock	N/A	N/A	479000	479000	N/A
Other Current Assets	N/A	N/A	N/A	N/A	N/A
Retained Earnings	N/A	N/A	-278.25 million	-274.93 million	N/A
Other Liabilities	N/A	N/A	N/A	N/A	N/A
Other Assets	N/A	N/A	1.39 million	1.9 million	N/A
Cash	N/A	N/A	47.87 million	54.41 million	N/A
Total Current Liabilities	N/A	N/A	32.8 million	31.87 million	N/A
Other Stockholder Equity	N/A	N/A	1.68 million	2.51 million	N/A
Property, Plant & Equipment	N/A	N/A	34.4 million	34.11 million	N/A
Total Current Assets	N/A	N/A	68.77 million	72.3 million	N/A
Long Term Investments	N/A	N/A	N/A	N/A	N/A
Net Tangible Assets	51.11 million	50.39 million	N/A	54.29 million	N/A
Short Term Investments	N/A	N/A	N/A	N/A	N/A
Long Term Debt	N/A	N/A	4.49 million	4.51 million	N/A
Inventory	N/A	N/A	7.78 million	8.02 million	N/A
Accounts Payable	N/A	N/A	N/A	8.52 million	N/A

Enzo Biochem, Inc (ENZ) Chart:

Enzo Biochem, Inc (ENZ) News:

Below you will find a list of latest news for Enzo Biochem, Inc (ENZ) from major news sources. You can filter the results to only show news from a specific source.

No recent news available

Enzo Biochem, Inc (ENZ) Options:

A stock option is a contract between two parties in which the stock option buyer (holder) purchases the right (but not the obligation) to buy/sell 100 shares of an underlying stock at a predetermined price from/to the option seller (writer) within a fixed period of time.

Expiration Date:

Options Type:

Moneyness:

Show entries

Search:

Expiration Date	Strike	Last Price	Type	Open Interest	Implied Volatility	In the Money
2025-04-17	2.5	0.05	CALL	117	1333.8	FALSE
2025-04-17	5	0.05	CALL	5	1335.28	FALSE
2025-04-17	7.5	0	CALL	0	1453.34	FALSE
2025-04-17	2.5	0	PUT	0	0	TRUE
2025-04-17	5	0	PUT	0	0	TRUE
2025-04-17	7.5	0	PUT	0	0	TRUE
2025-05-16	2.5	0	CALL	0	441.22	FALSE
2025-05-16	5	0	CALL	0	524.5	FALSE
2025-05-16	7.5	0	CALL	0	569.63	FALSE
2025-05-16	2.5	2.15	PUT	0	0	TRUE
2025-05-16	5	0	PUT	0	483.41	TRUE
2025-05-16	7.5	0	PUT	0	858.45	TRUE
2025-07-18	2.5	0.01	CALL	234	277.58	FALSE
2025-07-18	5	0	CALL	0	430.74	FALSE
2025-07-18	7.5	0	CALL	0	353.17	FALSE
2025-07-18	2.5	0	PUT	0	0	TRUE
2025-07-18	5	0	PUT	0	476.44	TRUE
2025-07-18	7.5	0	PUT	0	434.34	TRUE
2025-10-17	2.5	0.05	CALL	1	259.6	FALSE
2025-10-17	5	0	CALL	0	0	FALSE

Latest ENZ Trades:

Date	Shares	Price
Jun 13, 2022 6:09 PM EST	1	$2.21

Enzo Biochem, Inc (ENZ) SEC Filings:

An SEC filing is a financial statement or other formal document submitted to the U.S. Securities and Exchange Commission (SEC). Public companies, certain insiders, and broker-dealers are required to make regular SEC filings.

Form Type:

Show entries

Search:

Date	Form Type	View
2020-10-19	10-K (Annual report [Section 13 and 15(d), not S-K Item 405])
2020-08-12	11-K (Annual report of employee stock purchase, savings and similar plans)
2020-06-25	8-K (Current report)
2020-06-25	8-K (Current report)
2020-06-09	10-Q (Quarterly report [Sections 13 or 15(d)])
2020-06-08	8-K (Current report)
2020-04-29	4/A (Statement of changes in beneficial ownership of securities)
2020-04-29	4 (Statement of changes in beneficial ownership of securities)
2020-04-28	4 (Statement of changes in beneficial ownership of securities)
2020-04-28	4 (Statement of changes in beneficial ownership of securities)
2020-04-28	4 (Statement of changes in beneficial ownership of securities)
2020-04-24	8-K (Current report)
2020-04-14	8-K/A (Current report)
2020-04-09	8-K (Current report)
2020-03-06	UPLOAD (SEC-generated letter)
2020-03-06	10-Q (Quarterly report [Sections 13 or 15(d)])
2020-03-06	S-8 (Securities to be offered to employees in employee benefit plans)
2020-03-05	8-K (Current report)
2020-03-02	8-K (Current report)
2020-02-27	SC 13D/A (General statement of acquisition of beneficial ownership)

Enzo Biochem, Inc (ENZ) Insider Transactions:

Here you will find a list of insider trading activities (stock purchases, sales, and option exercises) reported by insiders of Enzo Biochem, Inc (ENZ). Company insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise.
Insider Ownership: 717%
Institutional Ownership: 6219%

Show entries

Search:

Transaction Date	Insider Name	Insider Title	Type	Shares Number	Shares Price	Total Transaction	Shares Held After Transaction
2020-02-18	PETER J IV CLEMENS	10% Share Holder	Buy	4,000.00	2.20	8,800.00	15,000.00
2020-02-14	PETER J IV CLEMENS	10% Share Holder	Buy	6,000.00	2.21	13,260.00	11,000.00
2019-08-20	MANAGEMENT CORP HARBERT	10% Share Holder	Buy	9,700.00	3.11	30,167.00	5,620,681.00
2019-08-16	MANAGEMENT CORP HARBERT	10% Share Holder	Buy	22,800.00	3.06	69,768.00	5,610,981.00
2019-07-23	MANAGEMENT CORP HARBERT	10% Share Holder	Buy	409,200.00	3.65	1,493,580.00	5,588,181.00
2019-07-22	MANAGEMENT CORP HARBERT	10% Share Holder	Buy	9,644.00	3.64	35,104.16	5,178,981.00
2019-05-30	MANAGEMENT CORP HARBERT	10% Share Holder	Buy	19,391.00	3.07	59,530.37	5,169,337.00
2019-05-29	MANAGEMENT CORP HARBERT	10% Share Holder	Buy	19,050.00	3.08	58,674.00	5,149,946.00
2019-05-28	MANAGEMENT CORP HARBERT	10% Share Holder	Buy	50,000.00	3.10	155,000.00	5,117,219.00
2019-05-28	MANAGEMENT CORP HARBERT	10% Share Holder	Buy	13,677.00	3.06	41,851.62	5,130,896.00
2019-05-20	MANAGEMENT CORP HARBERT	10% Share Holder	Buy	14,132.00	3.61	51,016.52	5,067,219.00
2019-01-14	BARRY W WEINER	Pres, CFO Prin Acct Ofcr Treas	Buy	2,226.00	2.70	6,010.20	1,136,918.00
2019-01-14	ELAZAR RABBANI	Chm of the Bd, CEO and Sec	Buy	2,782.00	2.70	7,511.40	1,661,003.00
2019-01-14	Dov Perlysky	Director	Buy	9,184.00	2.70	24,796.80	65,787.00
2019-01-14	GREGORY M. BORTZ	Director	Buy	9,184.00	2.70	24,796.80	93,699.00
2018-10-29	ELAZAR RABBANI	Chm of the Bd, CEO and Sec	Buy	10,000.00	3.35	33,469.00	1,848,668.00
2018-10-18	Dov Perlysky	Director	Buy	10,000.00	3.50	35,000.00	266,235.00
2018-10-18	Bruce A. Hanna	Director	Buy	15,000.00	3.52	52,786.50	37,816.00
2018-01-17	BARRY W WEINER	President, CFO, Treasurer, PAO	Sell	11,000.00	7.75	85,250.00	1,302,111.00
2018-01-17	BARRY W WEINER	President, CFO, Treasurer, PAO	Buy	30,802.00	2.88	88,709.76	1,313,111.00

Enzo Biochem, Inc

(NYSE:ENZ)

$1.13

STRONG BUY

Latest On Enzo Biochem, Inc (ENZ):

About Enzo Biochem, Inc (ENZ):

General

Valuation

Financials

Highlights

Share Statistics

Technicals

Dividends

Enzo Biochem, Inc (ENZ) Dividend Calendar:

Enzo Biochem, Inc (ENZ) Earnings History:

Enzo Biochem, Inc (ENZ) Company Financial Statements:

Income Statement:

Cash Flow:

Balance Sheet:

Enzo Biochem, Inc (ENZ) Chart:

Enzo Biochem, Inc (ENZ) News:

Enzo Biochem, Inc (ENZ) Options:

Latest ENZ Trades:

Enzo Biochem, Inc (ENZ) SEC Filings:

Enzo Biochem, Inc (ENZ) Insider Transactions: